NCT00251459View on ClinicalTrials.gov

A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

PHASE3CompletedINTERVENTIONAL
Enrollment

5,000

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

September 30, 2007

Conditions
Choroidal NeovascularizationAge-related Macular Degeneration
Interventions
DRUG

rhuFab V2 (ranibizumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00251459 - A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter